Skip to main content
Figure 5 | BMC Musculoskeletal Disorders

Figure 5

From: Lipopolysaccharide treatment suppresses spontaneously developing ankylosing enthesopathy in B10.BR male mice: The potential role of interleukin-10

Figure 5

FACS analysis of lymphocyte subpopulations in the spleens of LPS-treated and control LPS-untreated B10.BR males. A decreased percentage of B cells (CD19+) and an increased percentage of natural killer cells (CD3-CD49b+) after the second and the fourth LPS dose (A, B) and a decreased percentage of T cells (CD3+, CD4+) after the second LPS dose (A) were found in LPS-treated males. No differences in the percentage of B cells (CD19+), subpopulations of T cells (CD3+, CD8+, CD4+, and CD4+Foxp3+) and natural killer cells (CD3+CD49b+, CD3-CD49b+) were found between both groups 20–22 weeks after the fourth LPS dose (C). * p < 0.05, ** p < 0.01.

Back to article page